Indi Molecular
Cheryl Zimberlin, Ph.D., is a principal at M Ventures, the corporate Venture Capital arm of Merck KgAA, Darmstadt, Germany. M Ventures takes an active role in company creation and investment, with the mandate to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business. Prior to joining the team, she had a successful academic career, publishing in top-tier academic journals, including Nature. She holds a Ph.D. in Oncology and MSc in Biotechnology. Currently, she holds board positions in several M Ventures portfolio companies.
This person is not in the org chart
This person is not in any offices
Indi Molecular
Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics.